UNI-EN 7:"Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD
Firma: SOPHARMA ADSpis treści:
1. REPORT
2. INFORMATION ABOUT THE ENTITY
3. SIGNATURE OF PERSONS REPRESENTING THE COMPANY
Spis załączników:
| POLISH FINANCIAL SUPERVISION AUTHORITY | |||||||||||
|
| UNI - EN REPORT No | 7 | / | 2023 | |||||||
| Date of issue: | 2023-01-27 | ||||||||||
| Short name of the issuer | |||||||||||
| SOPHARMA AD | |||||||||||
| Subject | |||||||||||
| "Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD | |||||||||||
| Official market - legal basis | |||||||||||
| art. 56. 1. 2 of Act on Public Offering. | |||||||||||
| Unofficial market - legal basis | |||||||||||
| Contents of the report: | |||||||||||
| “Sopharma” AD (the Company) notifies that in compliance with the decision of the Board of Directors of "Sopharma" AD dated 26.10.2022, the Company submitted for approval to the Financial Supervision Commission an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD, UIC: 119055339 in "Sopharma“ AD under the conditions and in accordance with Chapter XVI of the Commercial Law and Art. 122 of the Law on Public Offering of Securities. | |||||||||||
| Annexes | |||||||||||
| File | Description | ||||||||||
| SFA_2023_Biopharm_merger_FSC_FF_espi.pdf SFA_2023_Biopharm_merger_FSC_FF_espi.pdf | "Sopharma" AD submitted for approval to the Financial Supervision Commission for an Agreement for conversion by merger of the subsidiary company "Biopharm-engineering" AD | ||||||||||
| SOPHARMA AD | |||||||||||||
| (fullname of the issuer) | |||||||||||||
| SOPHARMA AD | Farmaceutyczny (far) | ||||||||||||
| (short name of the issuer) | (sector according to clasification of the WSE in Warsow) | ||||||||||||
| 1220 | Sofia | ||||||||||||
| (post code) | (city) | ||||||||||||
| IlienskoShosse | 16 | ||||||||||||
| (street) | (number) | ||||||||||||
| +359 2 813 42 00 | +359 2 936 02 86 | ||||||||||||
| (phone number) | (fax) | ||||||||||||
| (e-mail) | (web site) | ||||||||||||
| nd | |||||||||||||
| (NIP) | (REGON) | ||||||||||||
| SIGNATURE OF PERSONS REPRESENTING THE COMPANY | |||||
| Date | Name | Position / Function | Signature | ||
| 2023-01-27 | Ognian Donev | Executive Director | |||
Cena akcji Sopharma
Cena akcji Sopharma w momencie publikacji komunikatu to 10.4 PLN. Sprawdź ile kosztuje akcja Sopharma aktualnie.
W tej sekcji znajdziesz wszystkie komunikaty ESPI EBI Sopharma.
